BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 10551576)

  • 1. Compound A uptake and metabolism to mercapturic acids and 3,3,3-trifluoro-2-fluoromethoxypropanoic acid during low-flow sevoflurane anesthesia: biomarkers for exposure, risk assessment, and interspecies comparison.
    Kharasch ED; Jubert C
    Anesthesiology; 1999 Nov; 91(5):1267-78. PubMed ID: 10551576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-dependent metabolism of fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), an anesthetic degradation product, to mercapturic acids and 3,3,3-trifluoro-2-(fluoromethoxy)propanoic acid in rats.
    Kharasch ED; Jubert C; Spracklin DK; Hoffman GM
    Toxicol Appl Pharmacol; 1999 Oct; 160(1):49-59. PubMed ID: 10502502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biotransformation of L-cysteine S-conjugates and N-acetyl-L-cysteine S-conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in human kidney in vitro: interindividual variability in N-acetylation, N-deacetylation, and beta-lyase-catalyzed metabolism.
    Gul Altuntas T; Kharasch ED
    Drug Metab Dispos; 2002 Feb; 30(2):148-54. PubMed ID: 11792683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of cytochrome P4503A in cysteine S-conjugates sulfoxidation and the nephrotoxicity of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in rats.
    Sheffels P; Schroeder JL; Altuntas TG; Liggitt HD; Kharasch ED
    Chem Res Toxicol; 2004 Sep; 17(9):1177-89. PubMed ID: 15377151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of low-flow sevoflurane and isoflurane effects on renal function using sensitive markers of tubular toxicity.
    Kharasch ED; Frink EJ; Zager R; Bowdle TA; Artru A; Nogami WM
    Anesthesiology; 1997 Jun; 86(6):1238-53. PubMed ID: 9197292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for metabolism of fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), a sevoflurane degradation product, by cysteine conjugate beta-lyase.
    Spracklin DK; Kharasch ED
    Chem Res Toxicol; 1996 Jun; 9(4):696-702. PubMed ID: 8831812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cysteine conjugate beta-lyase-dependent metabolism of compound A (2-[fluoromethoxy]-1,1,3,3,3-pentafluoro-1-propene) in human subjects anesthetized with sevoflurane and in rats given compound A.
    Iyer RA; Frink EJ; Ebert TJ; Anders MW
    Anesthesiology; 1998 Mar; 88(3):611-8. PubMed ID: 9523802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxicity of S-conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl) vinyl ether (Compound A) in a human proximal tubular cell line.
    Altuntas TG; Zager RA; Kharasch ED
    Toxicol Appl Pharmacol; 2003 Nov; 193(1):55-65. PubMed ID: 14613716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulfoxidation of cysteine and mercapturic acid conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A).
    Altuntas TG; Park SB; Kharasch ED
    Chem Res Toxicol; 2004 Mar; 17(3):435-45. PubMed ID: 15025515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of renal cysteine conjugate beta-lyase in the mechanism of compound A nephrotoxicity in rats.
    Kharasch ED; Thorning D; Garton K; Hankins DC; Kilty CG
    Anesthesiology; 1997 Jan; 86(1):160-71. PubMed ID: 9009951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glutathione S-conjugation of the sevoflurane degradation product, fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in human liver, kidney, and blood in vitro.
    Altuntas TG; Kharasch ED
    Toxicol Appl Pharmacol; 2001 Dec; 177(2):85-93. PubMed ID: 11740907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Compound A: toxicology and clinical relevance].
    Kharasch ED
    Anaesthesist; 1998 Nov; 47 Suppl 1():S7-10. PubMed ID: 9893874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of sevoflurane on the metabolism and renal effects of compound A in rats.
    Kharasch ED; Schroeder JL; Sheffels P; Liggitt HD
    Anesthesiology; 2005 Dec; 103(6):1183-8. PubMed ID: 16306730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nephrotoxicity of sevoflurane compound A [fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether] in rats: evidence for glutathione and cysteine conjugate formation and the role of renal cysteine conjugate beta-lyase.
    Jin L; Baillie TA; Davis MR; Kharasch ED
    Biochem Biophys Res Commun; 1995 May; 210(2):498-506. PubMed ID: 7755627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal toxicity with sevoflurane: a storm in a teacup?
    Gentz BA; Malan TP
    Drugs; 2001; 61(15):2155-62. PubMed ID: 11772127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of 19F-nuclear magnetic resonance and gas chromatography-electron capture detection in the quantitative analysis of fluorine-containing metabolites in urine of sevoflurane-anaesthetized patients.
    Orhan H; Commandeur JN; Sahin G; Aypar U; Sahin A; Vermeulen NP
    Xenobiotica; 2004 Mar; 34(3):301-16. PubMed ID: 15204701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunochemical evidence against the involvement of cysteine conjugate beta-lyase in compound A nephrotoxicity in rats.
    Njoku DB; Pohl LR; Sokoloski EA; Marchick MR; Borkowf CB; Martin JL
    Anesthesiology; 1999 Feb; 90(2):458-69. PubMed ID: 9952153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification in rat bile of glutathione conjugates of fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether, a nephrotoxic degradate of the anesthetic agent sevoflurane.
    Jin L; Davis MR; Kharasch ED; Doss GA; Baillie TA
    Chem Res Toxicol; 1996 Mar; 9(2):555-61. PubMed ID: 8839062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-flow sevoflurane compared with low-flow isoflurane anesthesia in patients with stable renal insufficiency.
    Conzen PF; Kharasch ED; Czerner SF; Artru AA; Reichle FM; Michalowski P; Rooke GA; Weiss BM; Ebert TJ
    Anesthesiology; 2002 Sep; 97(3):578-84. PubMed ID: 12218523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of renal and hepatic toxicity after four hours of 1.25 minimum alveolar anesthetic concentration sevoflurane anesthesia in volunteers.
    Ebert TJ; Messana LD; Uhrich TD; Staacke TS
    Anesth Analg; 1998 Mar; 86(3):662-7. PubMed ID: 9495434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.